SOFT TISSUE SARCOMA

This study tests a treatment made from a patient's own immune cells (called LN-145) for cancers like ovarian, triple-negative breast, anaplastic thyroid, and bone sarcomas that have not responded to standard therapy or have returned. The cells are taken from the tumor, grown in a…

This early-stage study tests a new cancer vaccine (p53MVA) combined with the immunotherapy drug pembrolizumab in people with advanced solid tumors that have not responded to other treatments. The vaccine helps the immune system recognize and attack cancer cells, while pembrolizum…

This early-stage study tests whether a treatment made from a patient's own tumor-fighting immune cells (TIL) is safe for children, teenagers, and young adults with solid tumors that have come back or stopped responding to standard treatments. About 40 participants will receive th…

This study tests whether combining two drugs—atezolizumab (an immunotherapy) and tivozanib (a targeted therapy)—can shrink tumors in cancers that typically don't respond to immunotherapy alone. About 29 adults with advanced bile duct, gallbladder, breast, neuroendocrine, ovarian,…

This early-phase study tests a new treatment for children and young adults (up to age 26) with solid tumors that have come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack a protein c…

This early-phase study tests a new drug (ADI-PEG 20) combined with chemotherapy and radiation before surgery for soft tissue sarcoma. The goal is to find the safest dose and see if it helps shrink tumors. Only 6 people are enrolled so far, and the study is actively monitoring for…

This study tests a new approach for people with advanced soft tissue sarcoma that cannot be easily removed with surgery alone. Participants receive a virus-based injection directly into the tumor along with radiation therapy before surgery. The goal is to see if this combination …

This early-stage study tests whether adding high-dose vitamin C to a standard chemotherapy drug (gemcitabine) can help control advanced soft tissue or bone sarcomas that cannot be removed by surgery or have spread. About 30 adults will receive the combination intravenously. The m…

This study tests a daily pill called cabozantinib in children and young adults (up to age 30) with rare cancers like sarcomas, Wilms tumor, and others that have come back or not responded to treatment. The drug works by blocking signals that help tumors grow and form blood vessel…

This study tests a more precise way to deliver radiation therapy to children and young adults with bone and soft tissue tumors. By using CT, MRI, and PET scans to map the tumor exactly, doctors can target the cancer while protecting healthy tissue. The goal is to improve tumor co…

This study tests a shorter course of high-dose radiation (hypofractionated radiotherapy) for people with soft tissue sarcoma that cannot be removed by surgery. The goal is to see if this approach can control the tumor for at least two years while limiting damage to nearby healthy…

This early-phase study tests a personalized cell therapy for children and young adults (ages 1–30) whose solid tumors have come back or not responded to standard treatment. Researchers take a patient's own immune T cells, modify them to recognize and attack cancer cells that carr…

This study tests whether combining two drugs (etrumadenant and zimberelimab) can shrink tumors or slow the disease in people with advanced dedifferentiated liposarcoma that has returned, spread, or cannot be removed by surgery. About 16 adults with this rare soft-tissue cancer wi…

This study tests whether a lower dose of radiation aimed at a smaller area after surgery can control soft tissue sarcoma just as well as the standard approach, while causing fewer long-term side effects. About 65 adults who had their tumor removed will receive the experimental ra…

This study compares two common blood thinners—aspirin and low molecular weight heparin—to see which works better at preventing dangerous blood clots after surgery for bone or soft tissue cancer in the pelvis or leg. About 2,868 adults who have had or will have such surgery will b…

This study tests a virus-based drug (T-VEC) combined with radiation for adults with newly diagnosed soft tissue sarcoma that can be removed by surgery. The goal is to see if this combination can destroy most of the tumor before surgery and to check for side effects. About 40 peop…

This study tests an oral drug called LOXO 292 in 36 children with advanced solid or brain tumors that have a specific genetic change (RET alteration). The goal is to see if the drug can shrink tumors and control the disease. Participants must have already tried standard treatment…

This early-phase study tests whether injecting a modified herpes virus (T-VEC) directly into tumors, combined with radiation therapy before surgery, is safe and tolerable for people with advanced soft tissue sarcoma. About 8 participants receive the combination to check for side …

This early-phase study tests whether a mix of drugs and targeted radiation can help the immune system recognize and attack hard-to-treat solid tumors. About 14 adults with advanced melanoma, breast cancer, or other solid cancers that cannot be surgically removed will receive inje…

This study looks at whether a personalized risk assessment tool called PERSARC can help adults with soft-tissue sarcoma understand their treatment options better and feel less conflicted about their decisions. About 120 patients will either receive standard care or use the tool d…

This study tests whether giving radiation over just 5 days before surgery for soft tissue sarcoma is practical and acceptable. About 16 adults with sarcoma in an arm, leg, or trunk will receive this shorter radiation course. The goal is to see if patients choose this option and h…